首页 > 产品中心 > 抗体 > 中和/阻断抗体

InVivoMAb Anti-Campylobacter jejuni subsp. wlaB/pglK Nanobody (Iv0202) (JN929010)

价格:
规格:
  • 100ug
  • 1mg
数量:
  • 概述

  • 图片

  • 参考文献

  • 产品说明书

概述
货号JN929010
品牌abinScience
描述
InVivoMAb Anti-Campylobacter jejuni subsp. wlaB/pglK Nanobody (Iv0202) [Iv0202] (JN929010) is a alpaca monoclonal antibody detecting Protein glycosylation K in ELISA, Neutralization.
种属反应性Campylobacter jejuni
应用ELISA, Neutralization
宿主Alpaca
同种型VHH-8His-Cys-tag
克隆号Iv0202
克隆类型Monoclonal
靶标Protein glycosylation K, 7.5.2.5, pglK, wlaB, Cj1130c
内毒素水平<0.01 EU/ug
纯度>95% as determined by SDS-PAGE.
相关产品 pH 7.4 Dilution Buffer
纯化方式Purified by Nickel column.
Accession号Q0P9C4
状态Liquid
保存溶液 0.01M PBS pH 7.4

Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.

稳定性和存储Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
背景

Protein glycosylation K (wlaB/pglK) is a ~64 kDa protein. Mediates the ATP-dependent translocation of the undecaprenylpyrophosphate-linked heptasaccharide intermediate across the cell membrane; this is an essential step during the N-linked protein glycosylation pathway. Transport across the membrane is effected via ATP-driven conformation changes. Most likely, only the polar and charged part of the glycolipid enter the substrate-binding cavity, and the lipid tail remains exposed to the membrane lipids during the transmembrane flipping process.

NoteFor research use only. Not suitable for clinical or therapeutic use.
图片
  • SDS-PAGE

    SDS-PAGE for InVivoMAb Anti-Campylobacter jejuni subsp. wlaB/pglK Nanobody (Iv0202).

参考文献
公式
质量 (g) = 浓度 (mol/L) × 体积 (L) × 分子量 (g/mol)
填写 质量、浓度、体积中的任意 2 项 + 分子量,自动计算未知值。
质量
=
浓度
×
体积
分子量 *
g/mol
公式
C₁ × V₁ = C₂ × V₂
填写 4 项中的任意 3 项,自动计算未知值。
母液
C₁ (起始浓度)
×
V₁ (起始体积)
=
工作液
C₂ (终浓度)
×
V₂ (终体积)

相关产品推荐